JNM
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH RSS TABLE OF CONTENTS
 QUICK SEARCH:   [advanced]


     


First published online July 17, 2009, 10.2967/jnumed.108.053322
This Article
Right arrow Figures Only
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
jnumed.108.053322v1
50/8/1229    most recent
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Related articles in JNM
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Møller, M.
Right arrow Articles by Gjedde, A.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Møller, M.
Right arrow Articles by Gjedde, A.
Journal of Nuclear Medicine Vol. 50 No. 8 1229-1236
© 2009 by Society of Nuclear Medicine

doi: 10.2967/jnumed.108.053322

Clinical Investigation

Parametric Mapping of 5HT1A Receptor Sites in the Human Brain with the Hypotime Method: Theory and Normal Values

Mette Møller, Anders Rodell and Albert Gjedde

Center of Functionally Integrative Neuroscience, Aarhus University, and Pathophysiology and Experimental Tomography Center, Aarhus University Hospitals, Aarhus, Denmark

Correspondence: For correspondence or reprints contact: Mette Møller, PET Center, Aarhus University Hospital, Nørrebrogade 44, 8000 Aarhus C, Denmark. E-mail: moller{at}pet.auh.dk

The radioligand [carbonyl-11C]WAY-100635 (11C-WAY) is a PET tracer of the serotonin 5HT1A receptors in the human brain. It is metabolized so rapidly in the circulation that it behaves more as a chemical microsphere than as a tracer subject to continuous exchange between the circulation and brain tissue. Although reference tissue methods are useful as analyses of uptake of some radioligands with indeterminate arterial input functions, their use to analyze 11C-WAY uptake and binding is challenged by the rapid plasma metabolism, which violates the assumption that regions of interest and reference regions continue to exchange radioligand with the circulation during the entire uptake period. Here, we proposed a method of calculation (Hypotime) that specifically uses the washout rather than the accumulation of 11C-WAY to determine binding potentials (BPND), without the use of regression analysis. Methods: A total of 19 healthy volunteers (age range, 23–73 y) underwent PET to test the Hypotime application of the chemical microsphere properties of 11C-WAY to identify regions of binding and nonbinding on the exclusive basis of the rate of washout of 11C-WAY. Results: The results of the Hypotime method were compared with the simplified but multilinearized reference tissue method (MLSRTM). The distribution of receptor BPND obtained with Hypotime was consistent with previous autoradiography of postmortem brain tissue, with the highest values of BPND recorded in the medial temporal lobe and decline of receptor availability with age. The values in the basal ganglia and cerebellum were negligible. The MLSRTM, in contrast, yielded lower BPND in all regions and only weakly revealed the decline with age. Conclusion: The simple and computationally efficient Hypotime method gave reliable values of BPND without the use of regression. The MLSRTM, on the other hand, appeared to be affected by the early disappearance of the radioligand from the circulation and the associated uncertain late presence of 11C-WAY in the circulation.

Key Words: neurotransmission • serotonin 5HT1A receptors • PET • 11C-WAY-100635 • Hypotime

COPYRIGHT © 2009 by the Society of Nuclear Medicine, Inc.


Related articles in JNM:

This Month in JNM

JNM 2009 50: 11A-12A. [Full Text]  






HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH RSS TABLE OF CONTENTS
JOURNAL OF NUCLEAR MEDICINE TECHNOLOGY THE JOURNAL OF NUCLEAR MEDICINE
Copyright © 2009 by the Society of Nuclear Medicine.